SELLAS Life Sciences Group, Inc. beat EPS estimates 53% of the time across 17 reported quarters (9 beats, 8 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | — | — | — | Miss |
| Q12026 FY2026 | $-0.06 | $-0.05 | +16.7% | Beat |
| 2026-05-11 | — | — | — | Miss |
| 2026-03-19 | — | — | — | Miss |
| 2025-11-12 | $-0.06 | $-0.06 | +5.3% | Beat |
| 2025-08-12 | $-0.08 | $-0.07 | +16.0% | Beat |
| 2025-05-13 | $-0.10 | $-0.07 | +30.0% | Beat |
| 2025-03-20 | $-0.11 | $-0.08 | +27.3% | Beat |
| 2024-11-13 | $-0.13 | $-0.10 | +23.1% | Beat |
| 2024-08-13 | $-0.16 | $-0.13 | +18.8% | Beat |
| 2024-05-14 | $-0.16 | $-0.21 | -31.3% | Miss |
| 2024-03-28 | $0.09 | $-0.25 | -388.4% | Miss |
Back to SLS overview · SLS holders · SLS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.